



European Patent Office
80298 MUNICH
GERMANY

Questions about this communication ?

Contact Customer Services at www.epo.org/contact



Roques, Sarah Elizabeth
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ
ROYAUME UNI

Date

02.03.17

Reference C108846A-EP SER	Application No./Patent No. 09013687.0 - 1412 / 2161336
Applicant/Proprietor ONO Pharmaceutical Co., Ltd., et al	

Decision to maintain the European patent in amended form (Art. 101(3)(a) EPC)

European Patent No. : 2161336
Filing date : 02.05.06
Priority claimed : 09.05.05/ USP 679466
21.11.05/ USP 738434
08.12.05/ USP 748919

**Designated States and
Patent proprietor(s)** : AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI
LT LU LV MC NL PL PT RO SE SI SK TR
ONO Pharmaceutical Co., Ltd.
1-5, Doshomachi 2-chome
Chuo-ku
Osaka-shi, Osaka 541-8526/JP

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI
LT LU LV MC NL PL PT RO SE SI SK TR
E. R. Squibb & Sons, L.L.C.
Route 206 & Province Line Road
Princeton, NJ 08540/US

is maintained as amended.

Maintenance is based on the documents as specified and notified previously.

The announcement that the European patent is being maintained as amended will be published in the European Patent Bulletin 17/13 on 29.03.17.

Your attention is drawn to the communication of 2016-11-30, regarding the requirements and time limits for submitting translations of the new European Patent Specification in the designated Contracting States.

Date

Application No. 09013687.0

Opposition division

1st Examiner:
Chapman R

2nd Examiner:
Pérez-Mato I

Chairman:
Renggli-Zulliger N

